Article Text

PDF
Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma
  1. A G P Konstas1,
  2. D Mikropoulos1,
  3. A-B Haidich2,
  4. K S Ntampos1,
  5. W C Stewart3,4
  1. 1
    Glaucoma Unit, 1st University, Department of Ophthalmology, Thessaloniki, Greece
  2. 2
    Department of Hygiene, Aristotle University of Thessaloniki, Greece
  3. 3
    PRN Pharmaceutical Research Network, LLC, Dallas, Texas, USA
  4. 4
    Carolina Eye Institute, University of South Carolina, Columbia, South Carolina, USA
  1. Dr W C Stewart, PRN Pharmaceutical Research Network, LLC, 5001 LBJ Freeway, Suite 700, Dallas, TX 75244, USA; info{at}prnorb.com

Abstract

Objective: To evaluate the 24 h efficacy and safety of the travoprost/timolol maleate fixed combination (TTFC) versus travoprost when both are dosed in the evening in primary open-angle glaucoma patients.

Methods: Prospective, double-masked, crossover, active-controlled, randomised 24 h comparison. After a 6 week medicine-free period, patients were randomised to either TTFC or travoprost for 8 weeks and were then switched to the opposite treatment for another 8 weeks. At the end of the washout and treatment periods, a 24 h pressure curve was performed.

Results: Thirty-two patients completed the study. The TTFC group demonstrated a lower absolute intraocular pressure level (2.4 mm Hg) for the 24 h curve and at all time points, compared with travoprost (p⩽0.047). The pressure reduction from untreated baseline was significantly different between treatments for all time points (p = 0.018). The mean 24 h pressure fluctuation was lower with TTFC (3.0 mm Hg) compared with travoprost (4.0 mm Hg, p = 0.001). No statistical difference existed between the two treatment groups for any adverse event (p>0.05).

Conclusions: This study suggests that when both drugs are dosed in the evening the TTFC provides improved intraocular pressure reduction, compared with travoprost, over the 24 h curve and for each individual time point in primary open-angle glaucoma patients.

Statistics from Altmetric.com

Footnotes

  • Funding: The clinical site was supported in part by an unrestricted grant from Alcon. The administrative site, Pharmaceutical Research Network, LLC, received no financial support for this study.

  • Competing interests: None.

  • Ethics approval: Ethics approval was provided by the Bioethics Committee of the Medical School of Aristotle University of Thessaloniki.

  • Patient consent: Obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.